Key Takeaways
- • Healthcare technology PE deals surged to $14.6 billion as of November 17, 2025, a 595% increase from $2 billion in 2024, marking the highest total since 2021 and reversing a multi-year funding slowdown in the sector.
- • Healthcare services PE funding declined sharply to $9 billion in 2025 from $15.2 billion in 2024, as PE investors shift capital away from provider-adjacent risks toward technology solutions addressing provider cost pressures and reimbursement challenges.
- • AI-driven administrative and clinical workflow solutions command premium valuations, with revenue cycle management and healthcare IT assets trading at 18.4x to low-20s EBITDA multiples, the highest levels observed in recent years according to Abry Partners and Capstone Partners data.
- • Federal regulatory support accelerated with CMS's new ACCESS model, FDA's TEMPO pilot, and HHS AI initiative, with 250+ healthtech startups indicating interest in the CMS program designed to fast-track technology-enabled care deployment.
- • Middle-market PE targets include outpatient care models, physician specialty platforms, and behavioral health, driven by CMS 2025 payment rate incentives favoring lower-cost settings and sustained demand for SaaS solutions integrated into provider workflows.
Summary
Private equity capital has undergone a decisive reallocation within the healthcare sector in 2025, with technology increasingly displacing services-focused investments. As of mid-November 2025, healthtech PE and venture capital deals reached $14.6 billion, representing a 595% surge from $2 billion recorded in 2024 and reaching levels not seen since the pandemic-driven telehealth boom of 2021. This reversal marks a dramatic shift from the sector's funding contraction between 2022 and 2024, when healthcare IT faced significant capital constraints.
The divergence reflects a fundamental strategic pivot among institutional PE investors confronting headwinds in healthcare services. PE funding for healthcare services declined from $15.2 billion in 2024 to $9 billion in 2025, with quarterly deal counts falling to 148 announced or closed transactions in Q3 2025 from 185 in the prior quarter. This pullback stems from persistent reimbursement pressures, rising operational costs, and regulatory complexity facing direct provider investments. In response, PE sponsors are redirecting capital toward technology solutions that address provider pain points—revenue cycle management, administrative workflow automation, clinical decision support, and care coordination platforms enabled by artificial intelligence.
Valuation metrics for high-performing healthtech assets have reached exceptional levels. Abry Partners reports observing revenue cycle management and healthcare IT deals trading at EBITDA multiples in the low-20s range, substantially above the 18.4x average recorded across 2021–2024 healthcare IT transactions, according to Capstone Partners data. T.J. Rose, managing partner of newly formed Ironleaf Capital, attributes sustained demand to solutions addressing clinical decision-making, cost containment, and administrative streamlining—areas where many proven companies require capital for scaling but face limited debt availability due to higher borrowing costs. This capital allocation dynamic positions AI-enabled software-as-a-service platforms as the primary focus for growth-oriented PE deployment.
Federal regulatory developments have reinforced this investment thesis. In December 2025, the Centers for Medicare & Medicaid Services launched its ACCESS model, a ten-year voluntary outcomes-based payment framework supporting technology-enabled care, with over 250 startups signaling participation interest. The FDA simultaneously introduced its TEMPO pilot to expedite digital health device approvals within the ACCESS ecosystem, targeting approximately 10 manufacturers across four clinical use areas. These initiatives reduce regulatory friction and create a structured pathway for scaling early-stage healthtech solutions.
Middle-market PE investors are prioritizing specific healthcare verticals experiencing favorable macro conditions. Outpatient care models, physician specialty platforms, and behavioral health remain primary targets, supported by CMS 2025 payment incentives favoring lower-cost ambulatory and ASC settings over inpatient procedures. Investor focus on physician-owned specialty groups and founder-led healthtech platforms reflects recognition of persistent fragmentation in provider markets and accelerating digital adoption. Despite macroeconomic volatility compressing valuations and lengthening deal timelines through mid-2025, demographic tailwinds and structural provider economics maintain healthcare on the shortlist for PE capital deployment.
The divergence reflects a fundamental strategic pivot among institutional PE investors confronting headwinds in healthcare services. PE funding for healthcare services declined from $15.2 billion in 2024 to $9 billion in 2025, with quarterly deal counts falling to 148 announced or closed transactions in Q3 2025 from 185 in the prior quarter. This pullback stems from persistent reimbursement pressures, rising operational costs, and regulatory complexity facing direct provider investments. In response, PE sponsors are redirecting capital toward technology solutions that address provider pain points—revenue cycle management, administrative workflow automation, clinical decision support, and care coordination platforms enabled by artificial intelligence.
Valuation metrics for high-performing healthtech assets have reached exceptional levels. Abry Partners reports observing revenue cycle management and healthcare IT deals trading at EBITDA multiples in the low-20s range, substantially above the 18.4x average recorded across 2021–2024 healthcare IT transactions, according to Capstone Partners data. T.J. Rose, managing partner of newly formed Ironleaf Capital, attributes sustained demand to solutions addressing clinical decision-making, cost containment, and administrative streamlining—areas where many proven companies require capital for scaling but face limited debt availability due to higher borrowing costs. This capital allocation dynamic positions AI-enabled software-as-a-service platforms as the primary focus for growth-oriented PE deployment.
Federal regulatory developments have reinforced this investment thesis. In December 2025, the Centers for Medicare & Medicaid Services launched its ACCESS model, a ten-year voluntary outcomes-based payment framework supporting technology-enabled care, with over 250 startups signaling participation interest. The FDA simultaneously introduced its TEMPO pilot to expedite digital health device approvals within the ACCESS ecosystem, targeting approximately 10 manufacturers across four clinical use areas. These initiatives reduce regulatory friction and create a structured pathway for scaling early-stage healthtech solutions.
Middle-market PE investors are prioritizing specific healthcare verticals experiencing favorable macro conditions. Outpatient care models, physician specialty platforms, and behavioral health remain primary targets, supported by CMS 2025 payment incentives favoring lower-cost ambulatory and ASC settings over inpatient procedures. Investor focus on physician-owned specialty groups and founder-led healthtech platforms reflects recognition of persistent fragmentation in provider markets and accelerating digital adoption. Despite macroeconomic volatility compressing valuations and lengthening deal timelines through mid-2025, demographic tailwinds and structural provider economics maintain healthcare on the shortlist for PE capital deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.